Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN

Reuters03-28 14:00

Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN

Vivoryon reported new analyses from its Phase 2 varoglutamstat program that were presented March 28 at World Congress of Nephrology in Yokohama.
Data review pooled kidney function findings from two independent Phase 2 studies, VIVIAD and VIVA-MIND, showing consistent effects on eGFR in participants with diabetes.
Subgroup analyses indicated larger eGFR effects in elderly participants with diabetes versus elderly participants without diabetes.
Results in participants with diabetes with lower baseline eGFR, mean 60 mL/min/1.73m2, showed effect sizes comparable to or higher than total diabetes subgroup.
Vivoryon also cited diabetic kidney disease mouse model data showing improvements in inflammation, glomerulosclerosis, kidney function, supporting further development in diabetes with more advanced chronic kidney disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivoryon Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603280200OMX_____CNEWS_EN_GNW1001172796_en) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622388320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622388320","market":"fut","top_or_hot":-1,"title":"Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vivoryon reported new analyses from its Phase 2 varoglutamstat program that were presented March 28 at World Congress of Nephrology in Yokohama.\n        </li>\n<li>\n          Data review pooled kidney function findings from two independent Phase 2 studies, VIVIAD and VIVA-MIND, showing consistent effects on eGFR in participants with diabetes.\n        </li>\n<li>\n          Subgroup analyses indicated larger eGFR effects in elderly participants with diabetes versus elderly participants without diabetes.\n        </li>\n<li>\n          Results in participants with diabetes with lower baseline eGFR, mean 60 mL/min/1.73m2, showed effect sizes comparable to or higher than total diabetes subgroup.\n        </li>\n<li>\n          Vivoryon also cited diabetic kidney disease mouse model data showing improvements in inflammation, glomerulosclerosis, kidney function, supporting further development in diabetes with more advanced chronic kidney disease.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VIVRF\">Vivoryon Therapeutics NV</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603280200OMX_____CNEWS_EN_GNW1001172796_en) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vivoryon reported new analyses from its Phase 2 varoglutamstat program that were presented March 28 at World Congress of Nephrology in Yokohama.\n        </li>\n<li>\n          Data review pooled kidney function findings from two independent Phase 2 studies, VIVIAD and VIVA-MIND, showing consistent effects on eGFR in participants with diabetes.\n        </li>\n<li>\n          Subgroup analyses indicated larger eGFR effects in elderly participants with diabetes versus elderly participants without diabetes.\n        </li>\n<li>\n          Results in participants with diabetes with lower baseline eGFR, mean 60 mL/min/1.73m2, showed effect sizes comparable to or higher than total diabetes subgroup.\n        </li>\n<li>\n          Vivoryon also cited diabetic kidney disease mouse model data showing improvements in inflammation, glomerulosclerosis, kidney function, supporting further development in diabetes with more advanced chronic kidney disease.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VIVRF\">Vivoryon Therapeutics NV</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603280200OMX_____CNEWS_EN_GNW1001172796_en) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL3LSVqX:1","article_id":"2622388320","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622388320","pubTimestamp":1774677621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivoryon reported new analyses from its Phase 2 varoglutamstat program that were presented March 28 at World Congress of Nephrology in Yokohama.Data review pooled kidney function findings from two independent Phase 2 studies, VIVIAD and VIVA-MIND, showing consistent effects on eGFR in participants with diabetes.Subgroup analyses indicated larger eGFR effects in elderly participants with diabetes versus elderly participants without diabetes.Results in participants with diabetes with lower baseline eGFR, mean 60 mL/min/1.73m2, showed effect sizes comparable to or higher than total diabetes subgroup.Vivoryon also cited diabetic kidney disease mouse model data showing improvements in inflammation, glomerulosclerosis, kidney function, supporting further development in diabetes with more advanced chronic kidney disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股"},"translate_title":"Vivoryon在WCN上展示新的2期varoglutamstat分析，支持糖尿病肾病目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Vivoryon presents new Phase 2 varoglutamstat analyses supporting diabetic kidney disease target at WCN\n    \n\n\n          Vivoryon reported new analyses from its Phase 2 varoglutamstat program that were presented March 28 at World Congress of Nephrology in Yokohama.\n        \n\n          Data review pooled kidney function findings from two independent Phase 2 studies, VIVIAD and VIVA-MIND, showing consistent effects on eGFR in participants with diabetes.\n        \n\n          Subgroup analyses indicated larger eGFR effects in elderly participants with diabetes versus elderly participants without diabetes.\n        \n\n          Results in participants with diabetes with lower baseline eGFR, mean 60 mL/min/1.73m2, showed effect sizes comparable to or higher than total diabetes subgroup.\n        \n\n          Vivoryon also cited diabetic kidney disease mouse model data showing improvements in inflammation, glomerulosclerosis, kidney function, supporting further development in diabetes with more advanced chronic kidney disease.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivoryon Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603280200OMX_____CNEWS_EN_GNW1001172796_en) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622388320","isCrawlerRequest":true}